MX361858B - Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. - Google Patents

Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.

Info

Publication number
MX361858B
MX361858B MX2015002239A MX2015002239A MX361858B MX 361858 B MX361858 B MX 361858B MX 2015002239 A MX2015002239 A MX 2015002239A MX 2015002239 A MX2015002239 A MX 2015002239A MX 361858 B MX361858 B MX 361858B
Authority
MX
Mexico
Prior art keywords
polyoxyl
fatty acid
treatment
ophthalmic formulation
ocular conditions
Prior art date
Application number
MX2015002239A
Other languages
English (en)
Other versions
MX2015002239A (es
Inventor
K Mitra Ashim
L Weiss Sidney
J Mcnally Eugene
Original Assignee
Sun Pharma Global Fze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361858(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Global Fze filed Critical Sun Pharma Global Fze
Publication of MX2015002239A publication Critical patent/MX2015002239A/es
Publication of MX361858B publication Critical patent/MX361858B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan formulaciones para administración tópica, como pueden ser formulaciones oftálmicas, y los métodos de uso de estas formulaciones. En algunos aspectos y modalidades, las formulaciones pueden incluir un lípido o ácido graso poliloxilo y/o un alcohol polialcoxilado y puede incluir nanomicelas. También se incluyen los métodos de tratamiento o prevención de enfermedades o padecimientos, como pueden ser las enfermedades o padecimientos oculares.
MX2015002239A 2012-08-24 2013-08-23 Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. MX361858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693189P 2012-08-24 2012-08-24
PCT/US2013/056513 WO2014032026A1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Publications (2)

Publication Number Publication Date
MX2015002239A MX2015002239A (es) 2016-01-08
MX361858B true MX361858B (es) 2018-12-18

Family

ID=50148510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002239A MX361858B (es) 2012-08-24 2013-08-23 Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.

Country Status (16)

Country Link
US (5) US8980839B2 (es)
EP (2) EP4218729A1 (es)
AU (1) AU2013305539B2 (es)
CA (2) CA3050298A1 (es)
DK (1) DK2887923T3 (es)
ES (1) ES2948387T3 (es)
FI (1) FI2887923T3 (es)
HK (1) HK1211867A1 (es)
HR (1) HRP20230559T1 (es)
HU (1) HUE062145T2 (es)
LT (1) LT2887923T (es)
MX (1) MX361858B (es)
PL (1) PL2887923T3 (es)
PT (1) PT2887923T (es)
SI (1) SI2887923T1 (es)
WO (1) WO2014032026A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
MX2016015211A (es) * 2014-05-23 2017-06-20 Ocular Tech Sarl Formulaciones topicas y usos de las mismas.
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US20180133217A1 (en) * 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
DK3373976T3 (da) * 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
EP3373924A4 (en) * 2015-11-12 2019-06-19 Sun Pharma Global FZE Topical formulations and uses thereof
PT3423076T (pt) * 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
WO2017190114A1 (en) 2016-04-29 2017-11-02 i-novion, Inc. Liquid pentablock co-polymer formulations for sustained delivery of therapeutics
PL3548091T3 (pl) * 2016-11-29 2022-03-28 Oculis SA Otrzymywanie stałych kompleksów cyklodekstryny do dostarczenia czynnego składnika farmaceutycznego do oczu
CN107334734B (zh) * 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR20220031909A (ko) 2019-07-01 2022-03-14 오쿨리스 에스에이 약물을 포함하는 수성 조성물의 pH를 안정화하는 방법
EP4013443A4 (en) * 2019-08-18 2023-10-04 IVIEW Therapeutics (Zhuhai) Co., Ltd. IN-SITU GEL-CONTAINING CYCLOSPORINE MICELLARS AS A SYSTEM FOR THE DELAYED RELEASE OF OPHTHALMIC ACTIVE INGREDIENTS
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
US11918275B2 (en) 2021-04-30 2024-03-05 Cilag Gmbh International Electrosurgical adaptation techniques of energy modality for combination electrosurgical instruments based on shorting or tissue impedance irregularity
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
EP4387589A4 (en) * 2021-08-20 2025-09-03 Sun Pharmaceutical Ind Ltd STABLE OPHTHALMIC FORMULATION OF CYCLOSPORINE AND PROCESS FOR ITS MANUFACTURE
KR20250096644A (ko) 2022-11-04 2025-06-27 클라리스 바이오, 인크. 크로마칼림의 국소 안구 전달

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2406A (en) * 1841-12-30 Construction of railroad-scbapers fob cleaning te-ie tracks from sl
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
PT1435910E (pt) 2001-10-19 2009-09-07 Isotechnika Inc Novos pré-concentrados de microemulsão de análogos da ciclosporina
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
ES2527753T3 (es) 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
JP4845378B2 (ja) 2002-08-12 2011-12-28 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド レソルビン：治療処置用のバイオテンプレート
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060020563A1 (en) * 2004-07-26 2006-01-26 Coleman Christopher R Supervised neural network for encoding continuous curves
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
EA010802B1 (ru) 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
US20090209599A1 (en) 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP1983977A4 (en) 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
FR2904568B1 (fr) * 2006-08-03 2008-09-05 Dynastar Skis Sa Procede de fabrication d'une planche de glisse
US20110190389A1 (en) 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090048929A1 (en) * 2007-08-15 2009-02-19 Paul Im Authenticated travel record
WO2009028674A1 (ja) 2007-08-29 2009-03-05 Wakamoto Pharmaceutical Co., Ltd. ラタノプロスト含有水性医薬組成物
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090286718A1 (en) * 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
US20090298956A1 (en) 2008-05-28 2009-12-03 Chowhan Masood A Self-preserved emulsions
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2437756A2 (en) * 2009-06-02 2012-04-11 Wu, Nian Pure peg-lipid conjugates
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
RU2012115103A (ru) * 2009-09-17 2013-10-27 Сэндзю Фармасьютикал Ко., Лтд. Водные глазные капли, содержащие латанопрост, и способ ингибирования адсорбции латанопроста полимером
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2798923A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
EP2846769A1 (en) 2012-05-11 2015-03-18 Cipla Limited Pharmaceutical composition
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
MX2016015211A (es) 2014-05-23 2017-06-20 Ocular Tech Sarl Formulaciones topicas y usos de las mismas.
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
EP3373924A4 (en) 2015-11-12 2019-06-19 Sun Pharma Global FZE Topical formulations and uses thereof
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
EP2887923B1 (en) 2023-04-05
US20160256521A1 (en) 2016-09-08
FI2887923T3 (fi) 2023-06-30
AU2013305539B2 (en) 2018-08-02
US8980839B2 (en) 2015-03-17
LT2887923T (lt) 2023-07-10
EP4218729A1 (en) 2023-08-02
US9937225B2 (en) 2018-04-10
SI2887923T1 (sl) 2023-09-29
CA2914472C (en) 2019-09-03
HK1211867A1 (en) 2016-06-03
US20140057854A1 (en) 2014-02-27
CA3050298A1 (en) 2014-02-27
US10441630B2 (en) 2019-10-15
EP2887923A4 (en) 2016-03-30
PL2887923T3 (pl) 2023-08-14
DK2887923T3 (da) 2023-07-03
EP2887923A1 (en) 2015-07-01
US20160256520A1 (en) 2016-09-08
WO2014032026A1 (en) 2014-02-27
MX2015002239A (es) 2016-01-08
AU2013305539A1 (en) 2015-03-12
US20150148299A1 (en) 2015-05-28
HRP20230559T1 (hr) 2023-09-15
HUE062145T2 (hu) 2023-10-28
CA2914472A1 (en) 2014-02-27
PT2887923T (pt) 2023-06-28
US20150165048A1 (en) 2015-06-18
ES2948387T3 (es) 2023-09-11

Similar Documents

Publication Publication Date Title
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
NZ704247A (en) Compositions and treatment for eye diseases and disorders
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
WO2013171764A3 (en) Ophthalmic formulations
NZ702967A (en) Diclofenac formulations
EP4360621A3 (en) Formulations of bendamustine
IN2015DN04151A (es)
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
PH12015502556A1 (en) Modified release formulation
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP4364810A3 (en) Topical formulations and uses thereof
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
PH12015501538A1 (en) Topical ocular analgesic agents
WO2013109202A3 (en) Pharmaceutical compounds comprising cefetamet
MX2013013286A (es) Formulación y método de preparación para obtener soluciones oftálmicas derivadas de quinolonas y una enzima proteasa con propiedades antinflamatorias y analgésicas.
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
NZ617069A (en) Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
MX2012001667A (es) Extracto de hojas de salix babylonica y leucaena leucocephala en el tratamiento de enfermedades parasitarias en el ganado ovino.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SUN PHARMA GLOBAL FZE

FG Grant or registration